Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development

Drug Discovery & Development

Boehringer, ViraTherapeutics partner to jointly develop oncolytic virus therapy platform Boehringer Ingelheim and ViraTherapeutics are collaborating to jointly develop a next generation oncolytic virus therapy platform and to investigate ViraTherapeutics’ lead candidate VSV-GP (Vesicular Stomatitis Virus (VSV) glycoprotein (GP)) alone and in combination with other therapies.
Drug Research > Drug Discovery & Development > News
Pfizer closes Medivation acquisition Pfizer has completed its acquisition of US biopharmaceutical firm Medivation for about $14bn.
Drug Research > Drug Discovery & Development > News Redx Pharma discovers breakthrough antibiotic compounds Redx Pharma has discovered a series of compounds that have the potential to create the first novel class of broad-spectrum antibiotics in 30 years.
Drug Research > Drug Discovery & Development > News
See more Drug Discovery & Development news

Latest Drug Discovery & Development News and Insight

View all Drug Discovery & Development news or find news targeted to your interests
C4X Discovery enters into multi-target, risk-sharing alliance with Evotec
C4X Discovery has entered into a multi-target, risk-sharing alliance (the agreement) with Evotec, a drug discovery alliance and development partnership firm.
Drug Research > Drug Discovery & Development > News
Sanofi secures $43m US funding to spur Zika vaccine development
The Biomedical Advanced Research and Development Authority (BARDA) within the Office of the Assistant Secretary for Preparedness and Response in the US Department of Health and Human Services is giving Sanofi $43.2m to fund the manufacture of a Zika vaccine for phase II development.
Drug Research > Drug Discovery & Development > News
Turing advances several experimental compounds into pre-clinical development
Turing Pharmaceuticals has advanced several experimental compounds into pre-clinical development.
Drug Research > Drug Discovery & Development > News
Allergan to acquire Tobira Therapeutics in $1.7bn deal
By PBR Staff Writer
Allergan has agreed to acquire clinical-stage biopharmaceutical firm Tobira Therapeutics in a deal worth about $1.7bn.
Drug Research > Drug Discovery & Development > News
Alnylam opens new development and commercial hub in Maidenhead, UK
RNAi therapeutics firm Alnylam Pharmaceuticals has opened a new development and commercial hub in Maidenhead, UK.
Drug Research > Drug Discovery & Development > News
Aerie Pharmaceuticals raises $125m in public offerings
Aerie Pharmaceuticals announced the pricing of a registered underwritten public offering of $75m of shares of its common stock at a price to the public of $29.50 per share, before deducting underwriting discounts and commissions and other estimated offering expenses.
Drug Research > Drug Discovery & Development > News
View all Drug Discovery & Development news or find news targeted to your interests